IQVIA Holdings Inc. (IQV)
| Previous Close | 229.60 |
| Open | 229.79 |
| Bid | 226.03 x 900 |
| Ask | 226.29 x 800 |
| Day's Range | 224.88 - 230.41 |
| 52 Week Range | 167.42 - 261.73 |
| Volume | |
| Avg. Volume | 863,054 |
| Market Cap | 41.166B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | 30.87 |
| EPS (TTM) | 7.32 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 271.24 |
ReutersAnalysis-Weight-loss drug forecasts jump to $150 billion as supply grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.
Simply Wall St.IQVIA Holdings Insiders Sell US$10m Of Stock, Possibly Signalling Caution
Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which may...
ZacksHere's Why You Should Hold on to IQVIA (IQV) Stock for Now
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
